Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients

Summary

Platelets from patients with type 2 diabetes are characterised by hyperactivation and high level of oxidative stress. Docosahexaenoic acid (DHA) may have beneficial effects on platelet reactivity and redox status. We investigated whether moderate DHA supplementation, given as a triglyceride form, may correct platelet dysfunction and redox imbalance in patients with type 2 diabetes. We conducted a randomised, double-blind, placebo-controlled, two-period crossover trial (n=11 post-menopausal women with type 2 diabetes) to test the effects of 400 mg/day of DHA intake for two weeks on platelet aggregation, markers of arachidonic acid metabolism, lipid peroxidation status, and lipid composition. Each two week-period was separated from the other by a six-week washout. Daily moderate dose DHA supplementation resulted in reduced platelet aggregation induced by collagen (-46.5 %, p< 0.001), and decreased platelet thromboxane B₂ (-35 %, p< 0.001), urinary 11-dehydro-thromboxane B₂ (-13.2 %, p< 0.001) and F2-isoprostane levels (-19.6 %, p< 0.001) associated with a significant increase of plasma and platelet vitamin E concentrations (+20 % and +11.8 %, respectively, p< 0.001). The proportions of DHA increased both in plasma lipids and in platelet phospholipids. After placebo treatment, there was no effect on any parameters tested. Our findings support a significant beneficial effect of low intake of DHA on platelet function and a favourable role in reducing oxidative stress associated with diabetes.

Keywords

Platelet aggregation - arachidonic acid - vitamin E - isoprostane - plasma and platelet lipid composition

• References

• 1 Guariguata L, Whiting DR, Hambleton I. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137-149.
• 2 Barr ELM, Zimmet PZ, Welborn TA. et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157.
• 3 Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications : a new perspective in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
• 4 Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Mad Indonses 2013; 45: 141-147.
• 5 Hamberg M, Svensson J, Samuelsson B. Thromboxanes : a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1975; 72: 2994-2998.
• 6 Véricel E, Januel C, Carreras M. et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004; 53: 1046-1051.
• 7 Feskens EJ, Virtanen SM, Rasanen L. et al. Dietary factors determining diabetes and impaired glucose tolerance: a 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18: 1104-1112.
• 8 De Caterina R, Madonna R, Bertolotto A. et al. N-3 fatty acids in the treatment of diabetic patients. Diabetes Care 2007; 30: 1012-1026.
• 9 Gao LG, Cao J, Mao QX. et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 2013; 226: 328-334.
• 10 Erkkilä AT, Matthan NR, Herrington DM. et al. Higher plasma docosahexaenoic acid is associated reduced progression of coronary atherosclerosis in women with CAD. J Lipid Res 2006; 47: 2814-2819.
• 11 Sacks FM, Stone PH, Gibson CM. et al. (HARP Research Group). Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 1995; 25: 1492-1498.
• 12 Yagi K. Lipid peroxides and human diseases. Chem Phys lipids 1987; 45: 337-351.
• 13 Véricel E, Polette A, Bacot S. et al. Pro- and antioxidant activities of docosahexaenoic acid on human blood platelets. J thromb Haemost 2003; 13: 566-572.
• 14 Guillot N, Caillet E, Laville M. et al. Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J 2009; 23: 2909-2916.
• 15 Lagarde M, Bryon PA, Guichardant M. et al. A simple and efficient method for platelet isolation from their plasma. Thromb Res 1980; 17: 581-588.
• 16 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
• 17 Boukhchache D, Lagarde M. Interactions between prostaglandin precursors during their oxygenation by human platelets. Biochim Biophys Acta 1982; 713: 386-392.
• 18 Croset M, Véricel E, Rigaud M. et al. Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid. Thromb Res 1990; 57: 1-12.
• 19 Therasse J, Lemonnier F. Determination of plasma lipoperoxides by high performance liquid chromatography. J Chromatogr 1987; 413: 237-241.
• 20 Bowyer DE, Leat WM, Howard AN. et al. The determination of the fatty acid composition of serum lipids separated by thin-layer chromatography; and a comparison with column chromatography. Biochim Biophys Acta 1963; 70: 423-431.
• 21 Woodman RJ, Mori TA, Burke V. et al. Effects of purified eicosapentaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003; 166: 85-93.
• 22 Venkatakrishnan P, Anuradha S, Bhattacharjee J. et al. Effects of low dose of omega-3 fatty acids on platelet functions and coagulation profile in Indian patients with type 2 diabetes mellitus with vascular complications : a prospective, preliminary study. J Indian Acad Clin Med 2007; 08: 45-52.
• 23 Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci 1983; 80: 3581-3584.
• 24 Catella F, Healy DLawson. et al. 11-dehydro-thromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
• 25 Davì G, Chiarelli F, Santilli F. et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-3203.
• 26 Kesavulu MM, Kameswararao B, Apparao Ch. et al. Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab 2002; 28: 20-26.
• 27 Azizi-Soleiman F, Jazayeri S, Eghtesadi S. Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, inflammation and body fat mass in patients with type 2 diabetes. Int J Prev Med 2013; 08: 922-928.
• 28 Praticò D. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147: 1-10.
• 29 Mori TA, Woodman RJ, Burke V. et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003; 35: 772-781.
• 30 McDonald DM, O’Kane F, McConville M. et al. Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids. Diabetes Care 2013; 36: 998-1005.
• 31 Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J. et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997; 40: 647-653.
• 32 Pirillo A, Catapano AL. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Atheroscler Suppl 2013; 14: 237-242.
• 33 Hartweg J, Farmer AJ, Perera R. and al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007; 50: 1593-1602.
• 34 von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446-2450.
• 35 Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 1996; 12: 3032-3039.
• 36 Conquer JA, Holub BJ. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997; 32: 341-345.
• 37 Shaikh SR, Kinnun JJ, Leng X. et al. How polyunsaturated fatty acids modify molecular organization in membranes: Insight from NMR studies of model systems. Biochim Biophys Acta. 2014 Epub ahead of print.
• 38 Jump DB, Botolin D, Wang Y. et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135: 2503-2506.
• 39 Mukherjee PKI, Marcheselli VL, Serhan CN. et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci 2004; 101: 8491-8496.
• 40 Chen PI, Véricel E, Lagarde M. et al. Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. FASEB J 2011; 25: 382-388.